Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USAArye Rubinstein, Leman Yel, Donald McNeil et al.|Clinical Immunology|2023Cited by 1